Ceryvyn Therapeutics Limited (UKJ2) Stock Statistics & Valuation Metrics
Total Valuation
Ceryvyn Therapeutics Limited has a market cap or net worth of EUR 8.55M. The enterprise value is -EUR 15.00M.
- Market Cap
- EUR 8.55M
- Enterprise Value
- -EUR 15.00M
Share Statistics
Ceryvyn Therapeutics Limited has 170,997,270 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 170,997,270
- Owned by Insiders
- ―
- Owned by Institutions
- 4.26%
Financial Efficiency
Ceryvyn Therapeutics Limited’s return on equity (ROE) is 2.91 and return on invested capital (ROIC) is -147.39%.
- Return on Equity (ROE)
- 2.91
- Return on Assets (ROA)
- -1.17
- Return on Invested Capital (ROIC)
- -147.39%
- Return on Capital Employed (ROCE)
- -1.54
- Revenue Per Employee
- 3,777.758
- Profits Per Employee
- -6.67M
- Employee Count
- 33
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Ceryvyn Therapeutics Limited is -1.16. Ceryvyn Therapeutics Limited’s PEG ratio is 0.07.
- PE Ratio
- -1.16
- PS Ratio
- 3971.55
- PB Ratio
- -3.36
- Price to FCF
- -3.07
- Price to Operating Cash Flow
- -1.58
- PEG Ratio
- 0.07
Income Statement
In the last 12 months, Ceryvyn Therapeutics Limited had revenue of 124.67K and earned -220.24M in profits. Earnings per share was -22.16.
- Revenue
- 124.67K
- Gross Profit
- 21.72K
- Operating Income
- -191.84M
- Pretax Income
- -229.65M
- Net Income
- -220.24M
- EBITDA
- -200.02M
- Earnings Per Share (EPS)
- -22.16
Cash Flow
- Operating Cash Flow
- -243.71M
- Free Cash Flow
- -137.45M
- Free Cash Flow per Share
- -0.25
Dividends & Yields
Ceryvyn Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -32.62%
- Earnings Yield
- -86.83%
Stock Price Statistics
- Beta
- 0.32
- 52-Week Price Change
- -98.87%
- 50-Day Moving Average
- 0.03
- 200-Day Moving Average
- 1.83
- Relative Strength Index (RSI)
- 1.35
- Average Volume (3m)
- 4,000
Important Dates
Ceryvyn Therapeutics Limited upcoming earnings date is Feb 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 28, 2026
- Next Earnings Date
- Feb 23, 2027
- Ex-Dividend Date
- ―
Financial Position
Ceryvyn Therapeutics Limited as a current ratio of 2.94, with Debt / Equity ratio of -186.85%
- Current Ratio
- 2.94
- Quick Ratio
- 2.94
- Debt to Market Cap
- 0.93
- Net Debt to EBITDA
- 0.15
- Interest Coverage Ratio
- -6.34
Taxes
In the past 12 months, Ceryvyn Therapeutics Limited has paid -9.41M in taxes.
- Income Tax
- -9.41M
- Effective Tax Rate
- 0.04
Enterprise Valuation
Ceryvyn Therapeutics Limited EV to EBITDA ratio is -2.32, with an EV/FCF ratio of -2.87.
- EV to Sales
- 3712.58
- EV to EBITDA
- -2.32
- EV to Free Cash Flow
- -2.87
- EV to Operating Cash Flow
- -2.87
Balance Sheet
Ceryvyn Therapeutics Limited has EUR 172.47M in cash and marketable securities with EUR 141.65M in debt, giving a net cash position of EUR 30.82M billion.
- Cash & Marketable Securities
- EUR 172.47M
- Total Debt
- EUR 141.65M
- Net Cash
- EUR 30.82M
- Net Cash Per Share
- EUR 0.18
- Tangible Book Value Per Share
- -EUR 0.89
Margins
Gross margin is 100.00%, with operating margin of -153885.37%, and net profit margin of -176665.73%.
- Gross Margin
- 100.00%
- Operating Margin
- -153885.37%
- Pretax Margin
- -184215.67%
- Net Profit Margin
- -176665.73%
- EBITDA Margin
- -159857.73%
- EBIT Margin
- -159940.37%
